Scarica l'app Stockscreener
241.95
0.54%
1.29
Dopo l'orario di chiusura:
241.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$240.66
Aprire:
$238.01
Volume 24 ore:
883.60K
Relative Volume:
0.83
Capitalizzazione di mercato:
$34.86B
Reddito:
$5.02B
Utile/perdita netta:
$1.31B
Rapporto P/E:
27.15
EPS:
8.91
Flusso di cassa netto:
$1.56B
1 W Prestazione:
+1.77%
1M Prestazione:
+17.93%
6M Prestazione:
-1.50%
1 anno Prestazione:
+11.53%
Intervallo 1D:
$237.00
$242.47
Intervallo di 1 settimana:
$233.54
$242.47
Portata 52W:
$179.42
$263.05
Resmed Inc Stock (RMD) Company Profile
Nome
Resmed Inc
Settore
Industria
Telefono
(858) 746-2400
Indirizzo
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Confronta RMD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
241.95 | 34.86B | 5.02B | 1.31B | 1.56B | 8.91 |
|
ISRG
Intuitive Surgical Inc
|
530.46 | 184.55B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
95.99 | 47.69B | 9.91B | 1.02B | 665.00M | 2.05 |
|
BDX
Becton Dickinson Co
|
165.15 | 47.42B | 20.87B | 1.50B | 2.59B | 5.24 |
|
COO
The Cooper Companies, Inc.
|
80.57 | 16.05B | 3.90B | 392.30M | 288.10M | 1.95 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-19 | Iniziato | Morgan Stanley | Overweight |
| 2025-01-16 | Iniziato | Goldman | Buy |
| 2025-01-10 | Iniziato | Piper Sandler | Neutral |
| 2024-12-13 | Iniziato | Stifel | Hold |
| 2024-09-24 | Iniziato | Robert W. Baird | Outperform |
| 2024-09-18 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Downgrade | Needham | Buy → Hold |
| 2024-06-25 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Aggiornamento | Needham | Hold → Buy |
| 2023-09-05 | Downgrade | UBS | Buy → Neutral |
| 2023-08-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Iniziato | UBS | Buy |
| 2023-04-14 | Iniziato | Mizuho | Buy |
| 2023-01-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-09-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-08-15 | Downgrade | CLSA | Buy → Outperform |
| 2022-08-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-28 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Aggiornamento | CLSA | Outperform → Buy |
| 2022-01-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-10-22 | Aggiornamento | CLSA | Underperform → Outperform |
| 2021-08-02 | Downgrade | CLSA | Outperform → Sell |
| 2021-08-02 | Downgrade | Needham | Buy → Hold |
| 2021-07-28 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Iniziato | RBC Capital Mkts | Underperform |
| 2021-06-28 | Downgrade | Citigroup | Buy → Neutral |
| 2021-06-22 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-06-22 | Iniziato | Robert W. Baird | Neutral |
| 2021-06-21 | Reiterato | Needham | Buy |
| 2021-06-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Aggiornamento | CLSA | Sell → Outperform |
| 2021-05-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-30 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Needham | Hold → Buy |
| 2020-11-02 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Iniziato | CLSA | Underperform |
| 2020-01-31 | Downgrade | UBS | Buy → Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Perform |
| 2019-11-22 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-16 | Downgrade | UBS | Buy → Neutral |
| 2019-05-06 | Aggiornamento | UBS | Neutral → Buy |
| 2019-04-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Iniziato | Goldman | Buy |
Mostra tutto
Resmed Inc Borsa (RMD) Ultime notizie
Is ResMed Inc.'s (NYSE:RMD) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st
Ex-Dividend Reminder: Seaboard, KB Home and ResMed - Nasdaq
ResMed Inc Reports Changes in CDIs and Securities for April 2025 - TipRanks
Jim Cramer on Viemed Healthcare (VMD): “Interesting, But I’m a ResMed Guy” - Yahoo Finance
ResMed Wins Invalidation of Sleep Apnea Tech Patent After Remand - Bloomberg Law News
Is It Smart To Buy ResMed Inc. (NYSE:RMD) Before It Goes Ex-Dividend? - Yahoo Finance
ResMed Corporation: GLP-1 Demand Generation Strategy to Expand Customer Base & Strengthen Their Position! - Smartkarma
Intuitive wins new FDA nod for single port robot; Resmed buys diagnostic facility - MedTech Dive
This ResMed Insider Reduced Their Stake By 72% - Yahoo Finance
Resmed acquires independent diagnostic testing facility VirtuOx - Yahoo Finance
Resmed Acquires Virtual Care Company VirtuOx - Medical Product Outsourcing
ResMed (RMD) Expands with VirtuOx Acquisition - GuruFocus
Resmed Acquires VirtuOx - Nasdaq
ResMed Buys VirtuOx for Undisclosed sum - marketscreener.com
Resmed (RMD) Expands Reach with Acquisition of VirtuOx | RMD Sto - GuruFocus
Resmed acquires virtual diagnostics company VirtuOx - MassDevice
Resmed (RMD) Expands Reach with Acquisition of VirtuOx | RMD Stock News - GuruFocus
Why ResMed (RMD) is a Top Growth Stock for the Long-Term - Yahoo Finance
ResMed announces it has acquired VirtuOx - TipRanks
Resmed Inc (RMD): Jim Cramer Says “Remarkable Stock” — Did GLP-1 Drugs Just Hand It a Lifeline? - Insider Monkey
This ASX medical device company has a Trump tariff exemption - MSN
Resmed Hires Chief Investor Relations Officer - HME Business
Press Release Distribution & PR Platform - ACCESS Newswire
ResMed Inc. Files Quarterly Report, Reinforces Market Position - MSN
ASX healthcare leader continues to prove the doubters wrong - Morningstar
What does Macquarie think ResMed shares are worth? - MSN
ResMed brushes off tariff threat - Intelligent Investor
ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market - MSN
ResMed Q1 2025: Strong Sales Growth and Strategic InitiativesNews and Statistics - IndexBox
ResMed Inc. (NYSE:RMD) Q3 2025 Earnings Call Transcript - Insider Monkey
ResMed Inc’s Earnings Call Highlights Growth and Innovation - TipRanks
ResMed Inc (RMD)'s Winning Formula: Financial Metrics and Compet - GuruFocus
ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Decoding ResMed Inc (RMD): A Strategic SWOT Insight - GuruFocus
ResMed Inc. stock rises Thursday, outperforms market - MSN
ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price ForecastResMed (NYSE:RMD) - Benzinga
ResMed (NYSE:RMD) Reports Strong Q3 Earnings Growth and Declares US$0.53 Dividend - Yahoo Finance
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates - MSN
ResMed Inc (RMD) Shares Up 11.28% on Apr 24 - GuruFocus
ResMed price target raised to $255 from $247 at RBC Capital - TipRanks
Jefferies Adjusts Price Target on ResMed to $245 From $270, Maintains Hold Rating - marketscreener.com
Morgan Stanley Adjusts Price Target on ResMed to $286 From $280, Maintains Overweight Rating - marketscreener.com
ResMed stock holds as Oppenheimer maintains Perform rating By Investing.com - Investing.com Canada
Texas Instruments Posts Better-Than-Expected Results, Joins Community Health Systems, Hasbro, ServiceNow, ResMed And Other Big Stocks Moving Higher On ThursdayArdagh Metal Packaging (NYSE:AMBP), Allegion (NYSE:ALLE) - Benzinga
Stifel maintains ResMed stock hold rating and $240 target - Investing.com
Stifel maintains ResMed stock hold rating and $240 target By Investing.com - Investing.com UK
ResMed stock price target raised to $255 at RBC Capital - Investing.com
Piper Sandler cuts ResMed stock price target to $248 - Investing.com
Piper Sandler cuts ResMed stock price target to $248 By Investing.com - Investing.com UK
ResMed (RMD) Target Price Lowered by Piper Sandler Following Ear - GuruFocus
ResMed (RMD) Price Target Reduced by Mizuho | RMD Stock News - GuruFocus
Resmed Inc Azioni (RMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):